PT2809681T - Anticorpos anti-asic1 e suas utilizações - Google Patents

Anticorpos anti-asic1 e suas utilizações

Info

Publication number: PT2809681T
Authority: PT; Portugal
Prior art keywords: asic1 antibodies; asic1; antibodies
Prior art date: 2012-01-31

Application number

PT13702876T

Other languages

English (en)

Inventor

Macdonald Lynn

L Lacroix-Fralish Michael

Gao Min

R Morra Marc

M Alessandri-Haber Nicole

Original Assignee

Regeneron Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-01-31

Filing date

2013-01-30

Publication date

2019-02-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47666522&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2809681(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-01-30 Application filed by Regeneron Pharma filed Critical Regeneron Pharma

2019-02-18 Publication of PT2809681T publication Critical patent/PT2809681T/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor

PT13702876T 2012-01-31 2013-01-30 Anticorpos anti-asic1 e suas utilizações PT2809681T (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US201261592837P	2012-01-31	2012-01-31
US201261644038P	2012-05-08	2012-05-08
US201261692925P	2012-08-24	2012-08-24

Publications (1)

Publication Number	Publication Date
PT2809681T true PT2809681T (pt)	2019-02-18

Family

ID=47666522

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PT13702876T PT2809681T (pt)	2012-01-31	2013-01-30	Anticorpos anti-asic1 e suas utilizações
PT182018234T PT3453723T (pt)	2012-01-31	2013-01-30	Anticorpos anti-asic1 e suas utilizações

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PT182018234T PT3453723T (pt)	2012-01-31	2013-01-30	Anticorpos anti-asic1 e suas utilizações

Country Status (33)

Country	Link
US (3)	US9150648B2 (pt)
EP (2)	EP3453723B1 (pt)
JP (1)	JP6302844B2 (pt)
KR (1)	KR102111941B1 (pt)
CN (1)	CN104093738B (pt)
AR (1)	AR089852A1 (pt)
AU (1)	AU2013215254B2 (pt)
CA (1)	CA2862332C (pt)
CL (1)	CL2014002019A1 (pt)
CO (1)	CO7020877A2 (pt)
CY (2)	CY1121368T1 (pt)
DK (2)	DK2809681T3 (pt)
EA (1)	EA028647B1 (pt)
ES (2)	ES2886123T3 (pt)
HK (1)	HK1199269A1 (pt)
HR (2)	HRP20211541T1 (pt)
HU (2)	HUE056335T2 (pt)
IL (2)	IL233410A0 (pt)
IN (1)	IN2014CN04645A (pt)
JO (1)	JO3547B1 (pt)
LT (2)	LT3453723T (pt)
MX (1)	MX358518B (pt)
MY (1)	MY168748A (pt)
NZ (1)	NZ626242A (pt)
PH (1)	PH12014501613B1 (pt)
PL (2)	PL2809681T3 (pt)
PT (2)	PT2809681T (pt)
RS (2)	RS58439B1 (pt)
SG (1)	SG11201403222UA (pt)
SI (2)	SI3453723T1 (pt)
TW (1)	TWI591073B (pt)
UY (1)	UY34603A (pt)
WO (1)	WO2013116296A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK2809681T3 (en)	2012-01-31	2019-03-11	Regeneron Pharma	ANTI-ASIC1 antibodies and uses thereof
CN106456732A (zh)	2014-04-15	2017-02-22	索伦托治疗有限公司	结合wisp1的抗体疗法
BR122018009619B1 (pt)	2014-05-16	2024-01-02	Ablynx N.V	Domínios variáveis de imunoglobulina aperfeiçoados
RU2746738C2 (ru)	2014-05-16	2021-04-20	Аблинкс Нв	Улучшенные вариабельные домены иммуноглобулина
CN105233286B (zh) *	2015-09-10	2018-10-30	上海交通大学医学院	含酸敏感离子通道调控剂的制剂及其在治疗瘙痒中的用途
CN105713089B (zh) *	2016-02-26	2019-08-06	上海科技大学	一种特异性抑制酸敏感离子通道i型的全人抗体
WO2018085441A1 (en) *	2016-11-01	2018-05-11	Berg Llc	Filamin b binding proteins and uses thereof
CN111936517A (zh) *	2018-01-26	2020-11-13	瑞泽恩制药公司	抗tmprss2抗体和抗原结合片段
EP3980456A4 (en) *	2019-06-04	2023-01-18	Shanghaitech University	AFFINITY MATURED ANTI-ASIC1A ANTIBODIES
JP2022540611A (ja) *	2019-07-11	2022-09-16	メモリアルスローンケタリングキャンサーセンター	Ｄｌｌ３をターゲッティングする抗体とその使用
CA3148131A1 (en) *	2019-07-23	2021-01-28	Shanghaitech University	Asic1 channel antagonist antibody
WO2021050857A1 (en) *	2019-09-13	2021-03-18	Memorial Sloan-Kettering Cancer Center	Anti-cd371 antibodies and uses thereof
AU2022326544A1 (en) *	2021-08-09	2024-02-29	Merck Patent Gmbh	Proteins that decouple t cell-mediated tumor cytotoxicity from release of pro-inflammatory cytokines
CA3230628A1 (en) *	2021-09-02	2023-03-09	John T. POIRIER	Anti-dll3 antibodies and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2759373B1 (fr)	1997-02-11	2001-05-04	Centre Nat Rech Scient	Nouveau canal cationique neuronal de mammifere sensible a l'acidite, son clonage et ses applications
AU9732498A (en)	1997-10-29	1999-05-17	Mcgill University	Dna encoding a human proton-gated ion channel and uses thereof
US6287859B1 (en)	1998-08-05	2001-09-11	Centre National De La Recherche	Identification, functional expression and chromosal localization of a sustained human proton-gated cation channel
CA2304494A1 (en)	2000-04-20	2001-10-20	Philippe Seguela	A novel heteromultimeric ion channel receptor and uses thereof
US6635432B1 (en)	2000-04-25	2003-10-21	University Of Iowa Research Foundation	Peptide potentiation of acid-sensory ion channel in pain
US7132505B1 (en)	2001-05-10	2006-11-07	Centre National De La Recherche Scientifique - Cnrs	Polypeptide inhibiting a proton-gated Na+ channel, a nucleic acid coding for such polypeptide and a method of manufacturing an ASIC1a channel blocker
CA2352702A1 (en)	2001-07-18	2003-01-18	Philippe Seguela	Novel human proton gated ion channel
AR039067A1 (es) *	2001-11-09	2005-02-09	Pfizer Prod Inc	Anticuerpos para cd40
ATE435239T1 (de) *	2002-03-29	2009-07-15	Schering Corp	Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen
US20070197583A1 (en)	2002-03-29	2007-08-23	Welsh Michael J	Novel compositions and methods for modulation of the acid-sensing ion channel (ASIC) for the treatment of anxiety and drug addiction
US20030186860A1 (en)	2002-03-29	2003-10-02	Welsh Michael J.	Novel compositions and methods for modulating the acid-sensing ion channel (ASIC)
US20070092444A1 (en)	2003-09-11	2007-04-26	The Uab Research Foundation	Inhibition of inward sodium currents in cancer
US20070281986A1 (en)	2004-02-03	2007-12-06	Collier Gregory R	Methods and Compositions for Modulating Satiety
JP2007530664A (ja)	2004-03-30	2007-11-01	ペインセプターファーマコーポレーション	ゲートイオンチャンネルを調節するための組成物及び方法
WO2005103081A2 (en)	2004-04-20	2005-11-03	Genmab A/S	Human monoclonal antibodies against cd20
US7192500B2 (en)	2004-04-30	2007-03-20	Kimberly-Clark Worldwide, Inc.	Process for making a garment including an absorbent assembly
US8030442B2 (en)	2004-09-16	2011-10-04	Morehouse School Of Medicine	Treatment of injury to the brain by inhibition of acid sensing ion channels
EP2284194A1 (en) *	2004-12-21	2011-02-16	AstraZeneca AB	Antibodies directed to angiopoietin-2 and uses thereof
AP2552A (en) *	2005-04-26	2013-01-08	Pfizer	P-cadherin antibodies
RS52643B (en) *	2006-06-02	2013-06-28	Regeneron Pharmaceuticals Inc.	HIGH AFINITY ANTIBODIES TO THE HUMAN IL-6 RECEPTOR
EP2975057A1 (en) *	2006-07-10	2016-01-20	Fujita Health University	Novel anti-cd73 antibody
EP2043650A2 (en)	2006-07-14	2009-04-08	Medical Research Council	Treatment for demyelinating disease
RU2448979C2 (ru) *	2006-12-14	2012-04-27	Ридженерон Фармасьютикалз, Инк.	Антитела человека к дельта-подобному лиганду-4 человека
US7598039B2 (en)	2007-01-30	2009-10-06	Academia Sinica	Treatment of insulin resistance
DK2137539T3 (da)	2007-04-03	2011-01-24	Ilegusavnid Genetics Resource Ct Minestry Of Social Affairs And Health	Amolorid følsomme calciumkanaler forbundet med paniklidelser
EP2150564A2 (en) *	2007-04-27	2010-02-10	ZymoGenetics, Inc.	Antagonists to il-17a, il-17f, and il-23p19 and methods of use
EP2288922B1 (en)	2008-05-08	2016-08-17	University of Utah Research Foundation	Sensory receptors for chronic fatigue and pain and uses thereof
US20090291150A1 (en)	2008-05-21	2009-11-26	University Of Iowa Research Foundation	Method and compositions for treating and preventing seizures by modulating acid-sensing ion channel activity
FR2932091B1 (fr)	2008-06-06	2012-12-28	Centre Nat Rech Scient	Effets analgesiques de la toxine peptidique apetx2
JP2012508017A (ja) *	2008-11-07	2012-04-05	ファブラスエルエルシー	抗ｄｌｌ４抗体及びその使用
JO3672B1 (ar) *	2008-12-15	2020-08-27	Regeneron Pharma	أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US8926976B2 (en) *	2009-09-25	2015-01-06	Xoma Technology Ltd.	Modulators
GB0922434D0 (en) *	2009-12-22	2010-02-03	Ucb Pharma Sa	antibodies and fragments thereof
CN102234316B (zh) *	2010-05-07	2014-01-29	中国人民解放军军事医学科学院毒物药物研究所	具有增强酸感受离子通道1a电流作用的多肽及其用途
DK2809681T3 (en)	2012-01-31	2019-03-11	Regeneron Pharma	ANTI-ASIC1 antibodies and uses thereof
US9371383B2 (en)	2012-01-31	2016-06-21	Regeneron Pharmaceuticals, Inc.	Anti-ASIC1 antibodies and uses thereof

2013
- 2013-01-30 DK DK13702876.7T patent/DK2809681T3/en active
- 2013-01-30 ES ES18201823T patent/ES2886123T3/es active Active
- 2013-01-30 CA CA2862332A patent/CA2862332C/en active Active
- 2013-01-30 LT LTEP18201823.4T patent/LT3453723T/lt unknown
- 2013-01-30 TW TW102103458A patent/TWI591073B/zh active
- 2013-01-30 LT LTEP13702876.7T patent/LT2809681T/lt unknown
- 2013-01-30 JP JP2014554950A patent/JP6302844B2/ja active Active
- 2013-01-30 HU HUE18201823A patent/HUE056335T2/hu unknown
- 2013-01-30 RS RS20190287A patent/RS58439B1/sr unknown
- 2013-01-30 KR KR1020147020682A patent/KR102111941B1/ko active IP Right Grant
- 2013-01-30 CN CN201380007553.3A patent/CN104093738B/zh active Active
- 2013-01-30 PL PL13702876T patent/PL2809681T3/pl unknown
- 2013-01-30 DK DK18201823.4T patent/DK3453723T3/da active
- 2013-01-30 WO PCT/US2013/023784 patent/WO2013116296A1/en active Application Filing
- 2013-01-30 JO JOP/2013/0036A patent/JO3547B1/ar active
- 2013-01-30 NZ NZ626242A patent/NZ626242A/en unknown
- 2013-01-30 HR HRP20211541TT patent/HRP20211541T1/hr unknown
- 2013-01-30 EA EA201491452A patent/EA028647B1/ru not_active IP Right Cessation
- 2013-01-30 AU AU2013215254A patent/AU2013215254B2/en active Active
- 2013-01-30 MY MYPI2014001721A patent/MY168748A/en unknown
- 2013-01-30 SI SI201331923T patent/SI3453723T1/sl unknown
- 2013-01-30 SG SG11201403222UA patent/SG11201403222UA/en unknown
- 2013-01-30 MX MX2014008541A patent/MX358518B/es active IP Right Grant
- 2013-01-30 EP EP18201823.4A patent/EP3453723B1/en active Active
- 2013-01-30 IN IN4645CHN2014 patent/IN2014CN04645A/en unknown
- 2013-01-30 US US13/753,836 patent/US9150648B2/en active Active
- 2013-01-30 SI SI201331343T patent/SI2809681T1/sl unknown
- 2013-01-30 RS RS20211284A patent/RS62454B1/sr unknown
- 2013-01-30 PT PT13702876T patent/PT2809681T/pt unknown
- 2013-01-30 EP EP13702876.7A patent/EP2809681B1/en active Active
- 2013-01-30 PL PL18201823T patent/PL3453723T3/pl unknown
- 2013-01-30 PT PT182018234T patent/PT3453723T/pt unknown
- 2013-01-30 ES ES13702876T patent/ES2707599T3/es active Active
- 2013-01-30 HU HUE13702876A patent/HUE042531T2/hu unknown
- 2013-01-30 AR ARP130100280 patent/AR089852A1/es active IP Right Grant
- 2013-01-31 UY UY34603A patent/UY34603A/es not_active Application Discontinuation
2014
- 2014-06-26 IL IL233410A patent/IL233410A0/en unknown
- 2014-07-11 PH PH12014501613A patent/PH12014501613B1/en unknown
- 2014-07-25 CO CO14162499A patent/CO7020877A2/es unknown
- 2014-07-30 CL CL2014002019A patent/CL2014002019A1/es unknown
- 2014-12-23 HK HK14112815.2A patent/HK1199269A1/xx unknown
2015
- 2015-09-09 US US14/848,452 patent/US20160002332A1/en not_active Abandoned
2017
- 2017-09-11 IL IL254416A patent/IL254416B/en active IP Right Grant
- 2017-09-28 US US15/719,220 patent/US10513557B2/en active Active
2019
- 2019-02-22 HR HRP20190358TT patent/HRP20190358T1/hr unknown
- 2019-02-27 CY CY20191100246T patent/CY1121368T1/el unknown
2021
- 2021-11-09 CY CY20211100968T patent/CY1124778T1/el unknown

Also Published As

Publication number	Publication date
KR102111941B1 (ko)	2020-05-18
PH12014501613A1 (en)	2014-10-13
EP3453723A2 (en)	2019-03-13
CY1124778T1 (el)	2022-11-25
RS58439B1 (sr)	2019-04-30
ES2886123T3 (es)	2021-12-16
PT3453723T (pt)	2021-09-07
EP2809681A1 (en)	2014-12-10
TWI591073B (zh)	2017-07-11
HUE042531T2 (hu)	2019-07-29
MY168748A (en)	2018-11-30
TW201335182A (zh)	2013-09-01
CO7020877A2 (es)	2014-08-11
EA028647B1 (ru)	2017-12-29
EP3453723A3 (en)	2019-04-10
EP3453723B1 (en)	2021-08-11
PH12014501613B1 (en)	2014-10-13
ES2707599T3 (es)	2019-04-04
IN2014CN04645A (pt)	2015-09-18
US10513557B2 (en)	2019-12-24
DK3453723T3 (da)	2021-09-13
MX2014008541A (es)	2014-10-24
SI2809681T1 (sl)	2019-04-30
JP2015508063A (ja)	2015-03-16
HRP20211541T1 (hr)	2021-12-24
CA2862332A1 (en)	2013-08-08
CA2862332C (en)	2021-05-18
HK1199269A1 (en)	2015-06-26
IL233410A0 (en)	2014-08-31
BR112014018651A2 (pt)	2017-07-04
RS62454B1 (sr)	2021-11-30
JO3547B1 (ar)	2020-07-05
WO2013116296A1 (en)	2013-08-08
AR089852A1 (es)	2014-09-24
SG11201403222UA (en)	2014-07-30
MX358518B (es)	2018-08-24
AU2013215254A1 (en)	2014-07-03
LT3453723T (lt)	2021-09-10
HUE056335T2 (hu)	2022-02-28
JP6302844B2 (ja)	2018-03-28
LT2809681T (lt)	2019-02-11
UY34603A (es)	2013-07-31
US20180222976A1 (en)	2018-08-09
CL2014002019A1 (es)	2015-01-16
AU2013215254B2 (en)	2017-08-31
US9150648B2 (en)	2015-10-06
HRP20190358T1 (hr)	2019-04-05
CN104093738B (zh)	2018-05-18
IL254416A0 (en)	2017-11-30
US20160002332A1 (en)	2016-01-07
PL2809681T3 (pl)	2019-05-31
EA201491452A1 (ru)	2014-11-28
CN104093738A (zh)	2014-10-08
CY1121368T1 (el)	2020-05-29
KR20140125363A (ko)	2014-10-28
EP2809681B1 (en)	2018-12-05
DK2809681T3 (en)	2019-03-11
IL254416B (en)	2018-03-29
NZ626242A (en)	2017-02-24
US20130195878A1 (en)	2013-08-01
PL3453723T3 (pl)	2022-01-03
SI3453723T1 (sl)	2021-11-30

Publication	Publication Date	Title
HUS2100034I1 (hu)	2021-10-28	ANGPTL3-ellenes antitestek és alkalmazásaik
HK1207092A1 (en)	2016-01-22	Anti-hla-b27 antibodies and uses thereof -hla-b27
HRP20190358T1 (hr)	2019-04-05	Antitijela protiv asic1 i njihova primjena
IL238559A0 (en)	2015-06-30	Antibodies against ceacam5 and their use
HK1200853A1 (en)	2015-08-14	Meditopes and meditope-binding antibodies and uses thereof
HK1207654A1 (en)	2016-02-05	Modified antibody regions and uses thereof
EP2832856A4 (en)	2016-01-27	ANTI-LAMP5 ANTIBODIES AND USE THEREOF
HK1205523A1 (en)	2015-12-18	Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof ---1(big-et-1)
EP2861623A4 (en)	2015-12-02	NEW SPECIFIC CLEC14A ANTIBODY AND USES THEREOF
GB201208372D0 (en)	2012-06-27	Antibodies and uses thereof